New Update #1 New Blockbuster Biotech Stock Silo Pharma (SILO) Set to EXPLODE
As Wall Street & Silicon Valley Invest Heavy Into This Space!
Dear Fellow Trader,
What if you could buy shares of Pfizer when it was a tiny, little-known company?
If you bought and held this biotech stock, even if all you bought is a few thousand bucks, you would be a multi-millionaire right now.
I’ve identified the next early-stage biopharmaceutical stock that could potentially ride the next biotech breakout wave.
Immediately turn your attention to Silo Pharma Inc. (SILO)
Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research to innovatively address underserved conditions including Fibromyalgia, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.
Wall Street & Silicon Valley Leaders Are Rushing
to Support Psychedelic Medicine
As psilocybin boldly merges into modern pharmacopeia, the emerging field of psychedelic medicine continues forward amidst this electrifying renaissance. Pioneers such as MAPS, Usona Institute and Compass Pathways have been awarded the coveted “breakthrough status” for their psilocybin-based therapies by the US Food & Drug Administration. This designation marked a historic moment for the overall psychedelic revolution and has caught the attention of various notable investors from Wall Street and Silicon Valley.
Peter Thiel, the notable billionaire backer of Compass Pathways, is the co-founder of PayPal and one of Facebook’s first major investors. He is also the chairman of aforementioned Palantir Technologies, which posted its best week since it went public in September, adding about $17 billion in market value as a broad rally in tech stocks helped fuel gains in the software maker.
Currently, Palantir is one of the tech industry’s most valuable private companies with a whopping valuation of $20 billion dollars. Thiel’s combined investments in Palantir and Compass Pathways highlights the significant shift in attention towards psychedelics from big players in Wall Street and Silicon Valley.
Looking at Thiel’s track record along with the significant attention towards psychedelics from big players in Wall Street and Silicon Valley, "Thiel may be onto something by investing in the psilocybin sector."
Introducing... SILO!
Now Turn Your Complete Attention to SILO
Wednesday's Focus Stock...
For investors of Silo Pharma, Inc. (SILO), a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, and general supporters of the psilocybin and ‘magic mushroom’ market, the passage of a ballot measure in Oregon just a few weeks ago to allow licensed providers to administer the hallucinogenic substance found in magic mushrooms is a significant development. As some may recall, Oregon was the first state to decriminalize the possession of small amounts of cannabis, and among the first to authorize its use for medical purposes.
Pioneering Oregon then proved a safe and regulated commercial market for cannabis and state after state continues to follow. It is worth noting that Washington D.C. passed a similar measure for mushroom based psychedelics.
And what is also of interest is that as these seminal legislative changes occur, Silo Pharma seeks to develop its own standing in the markets, having recently announced its transition from the OTC Pink Market to the OTCQB® Venture Market.
It’s a significant move through the transparency required of OTCQB companies, being quoted on a more senior quotation medium, and introducing the Company to a possible greater pool of retail investors and institutions.
Legalized psilocybin is in its infancy, and Silo Pharma appears to be in a nascent phase of its business plan despite a partnership with a major university already in place. As these new markets open up in Oregon and D.C., Silo is preparing to meet the moment.
And now to add more Breakout-Fuel to this bullish pick is their latest Blockbuster Patent News!
Silo Pharma, Inc. Announces Filing of Three
U.S. Provisional Patent Applications
Each Provisional Patent Application Relates to Psilocybin
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced the filing of three distinct U.S. Provisional Patent applications with the U.S. Patent and Trademark Office ("USPTO") pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin.
“Each of these provisional patents relates to the continued research and development of the central nervous system-homing peptides covered by the UMD option agreement to deliver certain compounds,” stated Eric Weisblum, Chairman and CEO of Silo Pharma.” We are excited to have taken this important action with respect to our recently announced collaboration with UMD.”
A provisional patent application is a critical step on the road to commercial viability. As the climate for intellectual property rights becomes more and more competitive, a provisional patent application successfully establishes an early effective filing date and allows the patent applicant or a licensee to ascribe the phrase "patent pending" to any product development and methodologies associated with the patent’s subject matter.
“These patent applications, together with Silo’s efforts to bring scientific talent, resources, and industry leaders together, allows the Company to continue its development of novel therapeutics in the psychedelic category,” stated Mr. Weisblum.
SILO also has several more bullish catalysts working in its favor:
Another bullish catalyst is SILO recently appointed of Dr. Matthew Johnson of John Hopkins University as a member of the advisory board.
Dr. Matthew W. Johnson, Ph.D., a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins, is one of the world’s most published scientists on the human effects of psychedelics and has conducted seminal research in the behavioral economics of drug use, addiction and risk behavior.
Working with psychedelics since 2004, Dr. Johnson published psychedelic safety guidelines in 2008, helping to resurrect psychedelic research. He is the Principle Investigator on research showing promising data for psilocybin in treating tobacco addictions, and on funded studies investigating psilocybin in the treatment of opioid dependence and PTSD. In 2016, Dr. Johnson and colleagues published the largest study of psilocybin in treating cancer distress.
“Matt has long been recognized for his behavioral research in psychedelics and pharmacology,” added Weisblum. “His experience and talents will be invaluable as we accelerate our pursuit of market opportunities for the application of psychedelic drug therapies. We welcome Matt to our advisory board and look forward to leveraging his insights and expertise.”
Dr. Johnson was 2019 President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association and is current President of the International Society for Research on Psychedelics, an organization he founded with colleagues. He has received continuous NIH funding as Principal Investigator since 2009. He has reviewed for more than 75 journals and has served as guest editor on two special issues on psychedelics.
Dr. Johnson has reviewed grants for NIH, NSF, the US Military, and multiple governments outside of the US. He is a standing member of the Addictions Risks and Mechanisms (ARM) NIH study section. He has provided invited presentations in 13 nations.
Another bullish catalyst is SILO to Explore Unique Peptide Delivery of Psilocybin Utilizing this Novel Technology Represents Key Differentiator in Emerging Psilocybin Space.
SILO announced that it has executed an option agreement with the University of Maryland, Baltimore with respect to the exploration of the potential use of central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology. Silo Pharma’s intends to explore the development of unique therapeutics that utilize these CNS Homing Peptides. Silo plans on initiating studies to evaluate the potential use of this invention to deliver Psilocybin based therapeutics directly to targeted areas of a patient.
This technology refers to phage-encoded peptides identified as being unique, inflamed CNS-specific markers. These peptides zero in on the spinal cord and, to a lesser extent, the cerebellum, in a rodent model of Multiple Sclerosis (MS). These peptides are designed to address many challenges, as they are expected to be pathology-specific (damaged, inflamed tissue only), are tissue specific (CNS), and can be used as an imaging tool for inflammation of the spinal cord. As such, Silo Pharma believes that they may be used in the detection of diseased tissue and for targeting therapeutic agents to the CNS to treat MS and other neuroinflammatory diseases.
“The option agreement gives Silo access to a potential unique and vital approach which significantly differentiates us within the Psilocybin space,” stated Eric Weisblum Chairman and CEO of Silo Pharma. “The ability to deliver psilocybin and other psychedelic compounds directly to targeted areas of the body with this technology could be significant by increasing the efficacy of the treatment while reducing the amount of medicine needed. There is a tremendous need for creative and unique therapeutics for patients suffering from rare diseases. We believe this novel approach coupled with our planned research of psilocybin as a therapeutic presents an exciting opportunity for the company.”
As you can see, there are multiple bullish catalysts signaling breakout gain potential!
It’s important to remember that historically, small-cap biotech, biopharmaceutical,
life sciences, nutraceutical and therapeutics companies have been my biggest gainers that are cut from the same cloth as SILO!
I am urging all of our members to add SILO to the top of their watch list right now, and be ready Wednesday morning at the opening bell!
?SamuraiStocks
Trading Research Team
